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http://dx.doi.org/10.1016/j.jfma.201Cancer and human immunodeficiency virus (HIV) are both scary things to have in your body, but
a new treatment is successfully using the latter against the former. Recent news reports,
among others in the New York Times, talked about this new cure for leukemia by using HIV.
This mini-review puts this news in perspective and provides a broader view as there appear
to be several areas where clinical research on HIV and leukemia seem to connect. The topics
covered range from antiviral gene therapy approaches using HIV-based lentiviral vectors to the
risk of leukemia induction by these integrating vectors, and from an anti-leukemia transplan-
tation strategy that turned out to provide a functional cure for HIV, to novel vaccination ap-
proaches.
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Much recent progress has been reported in the field of gene
therapy. Immunotherapy based on chimeric antigen re-
ceptor molecules that are directed against surface markers
on cancer cells is one of the promising approaches. In this
procedure, the T cells of a leukemia patient are modified
with a HIV-based lentiviral vector to deliver the anti-leu-
kemia transgene. We will discuss the ins and outs of recent
publications in this field and discuss the confusion in the
media about the use of HIV was used to fight leukemia.va.nl.
ight ª 2013, Elsevier Taiwan LLC
3.01.009Retroviral and lentiviral vectors and the risk of
leukemia induction
g-Retroviral vectors were frequently used to obtain robust
and stable genetic modification of human T lymphocytes
because these vectors can efficiently integrate within the
genome and ensure that the inserted transgene is passed to
the progeny of the transduced cells. Subsequently, lenti-
viral vectors were developed, which are in fact largely
based on the human immunodeficiency virus (HIV) genome.
HIV is also a member of the Retroviridae family and the
lentiviral vectors share the unique property of being able to
integrate into the host cell genome, which makes them the& Formosan Medical Association. All rights reserved.
442 B. Berkhoutdelivery vehicle of choice when a durable therapeutic ef-
fect is needed. Additional benefits of the lentiviral over
retroviral vector system include the ability to transduce
non-dividing cells.
However, genome integration is also considered a
potentially unsafe property of gene therapy vectors.
Several insertions next to a proto-oncogene were linked to
leukemia induction in patients treated with the first-
generation retroviral vectors.1,2 Such serious adverse ef-
fects were observed using stem and progenitor cell thera-
pies, but the safety profile of retroviral vectors in T cells is
so far excellent. Furthermore, the third-generation “self-
inactivating” lentiviral vectors were specifically designed
to avoid such insertional oncogenesis events, and the initial
clinical results with stem cells are reassuring.3HIV-based vectors for gene therapy against
leukemia
The recent news reports concerned the effective treatment
of a 6-year-old girl by a research team of the Abramson
Cancer Center at the University of Pennsylvania led by Dr
Carl June. This clinical success was presented at the
American Society of Hematology (ASH) annual meeting in
Atlanta, Georgia (8e11 December, 2012). She was selected
as a patient for the experimental technique after 2 years of
battling with lymphoblastic leukemia, where chemotherapy
failed to either cure the disease or result in a period of
remission long enough to consider a bone marrow trans-
plant. Testing, 2 months after the procedure, revealed no
sign of cancer and 6 months later she is still in remission and
is now back at school. What is the experimental therapy
about, does it really use HIV, and how novel is this news?
In fact, the same approach had already been used by the
same team on several adult patients and these results were
published in 2011,4,5 but she was the first child to undergo
this experimental adoptive T cell transfer procedure.
The pursuit of tumor-reactive Tcells as a cancer therapy was
originally spurred by the discovery of the graft-versus-
leukemia effect in patients undergoing allogeneic hemato-
poietic stem cell transplantation.6 Chronic lymphocytic
leukemia (CLL) is themost common type of this blood disease
that strikes some 15,000 people in the United States and kills
4300 each year. Chemotherapy and radiation can hold this
form of leukemia at bay for years, but until now the only cure
has been a bone marrow transplant, which is effective only
half the time, requires a matching donor, and often causes
life-threatening effects such as opportunistic infections.
TheTcells of patientsweremodified to express a chimeric
antigen receptor (CAR) with specificity for the B cell antigen
CD19, which has expression limited to normal and malignant
B cells. The HIV link comes from the use of a lentiviral vector
in an ex vivo gene therapy protocol that transduces the pa-
tient’s own T cells to harness them against leukemic B cells.
The CAR molecule was coupled to a combination of co-
stimulatory domains of CD137 and CD3-z. The initial patient
received a low dose of 1.5  105 modified T cells/kg 4 days
after receiving chemotherapy for depletion of lymphocytes.4
Tumor lysis syndrome with fever, aches and pains was
apparent at 22 days after treatment, which coincided with
the induction of the cytokines interferon-g and interleukin-6. The number of circulating CAR-positive T cells vigorously
increased nearly 1000 times compared with the level
detected the day after infusion. Engineered Tcells persisted
at high levels for 6 months in the blood and bone marrow,
accompanied by a profound loss of normal B cells and leu-
kemia cells that express CD19. Remission was ongoing 10
months after treatment.
Such prominent anti-leukemia activity points to sus-
tained effector functions of the CAR-modified T cells, which
is likely attributed to the replicative capacity of the
transferred cells. This poses a major advantage over pre-
vious attempts in which the re-injected T cells killed a few
cancer cells and then died out. This durable therapeutic
effect also provides a major advantage over other thera-
peutic options, e.g., using antibodies. The two studies re-
ported tumor responses in three patients with advanced
CLL,4,5 now followed by the first treatment of a child. The
news reports indicate that up to 12 patients were treated in
total (http://rt.com/news/girl-leukemia-treatment-hiv-
702/). Three adults had complete remissions, four had
improved conditions, but did not beat the disease
completely, one is still in a too-early stage to evaluate, and
two patients saw no effect from the treatment. Apparently,
a second child was treated who showed an initial response,
but eventually relapsed. Thus, T cell therapy appears to be
a promising medical breakthrough that may replace bone
marrow transplants, but there is a need to conduct addi-
tional trials and to optimize the method as several previous
breakthroughs in the cancer field have shown initial success
and subsequent failure. Whereas funding of the initial trial
turned out to be difficult, likely because the approach was
too novel and/or risky, the new results may accelerate the
fundraising process. In the future, attempts should tackle
the commercialization of this type of genetic medicine,
which remains challenging given the complex biology
involved and will require significant scrutiny from regula-
tory bodies, such as the Food and Drug Administration
before coming to the market.
Other cancers may also be targeted with this new
approach, e.g., hard-to-treat cancers such as mesotheli-
oma and pancreatic cancer. In order to attack large tumors
with adoptive cellular therapy, it seems pivotal that the
T cells proliferate to achieve an appropriate effector-to-
target cell ratio in vivo. Thus, approaches to safely increase
the proliferative potential of T cells and their trafficking to
tumors are needed.
The treated patients may exhibit B cell depletion and
hypogammaglobulinemia, which is an expected toxic effect
that is manageable.7 Targeting of B cells with rituximab
through the CD20 molecule is an effective and relatively
safe strategy for patients with B cell neoplasm. However, B
cell loss may cause substantial problems in the future
treatment of non-CLL tumor types. Safety measures may
range from simple protocol modifications (e.g. infusion of a
lower number of T cells) to intricate novel strategies (e.g.
incorporation of an inducible cellular suicide switch).HIV virotherapy for leukemia
In a laboratory setting, replication-competent HIV variants
have also been proposed as therapeutic agents against
HIV and leukemia 443leukemias. This so-called virotherapy forms a relatively
novel strategy that is based on the selective replication of
modified viruses in cancer cells, e.g., the use of an engi-
neered adenovirus in the treatment of head and neck
cancer.8 We explored the possibility of generating
leukemia-specific HIV variants based on the observation
that several accessory viral proteins are not needed for HIV
replication in transformed T cell lines, yet are important for
virus replication in primary cells. A minimized derivative of
HIV with five gene deletions (vif, vpR, vpU, nef and U3) was
demonstrated to replicate in several leukemic T cell lines,
but not in normal peripheral blood mononuclear cells.9 To
improve the safety of such a therapeutic agent, a drug-
inducible control switch was subsequently incorporated.10
Live, attenuated HIV as a vaccine approach
Similar safety concerns relate to the use of live, attenuated
HIV variants as vaccine candidates to protect against a
future infection. Such variants can completely protect
rhesus macaques from subsequent challenge with the highly
pathogenic, wild-type virus.11 Although this degree of ef-
ficacy is in sharp contrast to that achieved with a wide
variety of alternative vaccination strategies, safety con-
cerns remain. Protection is inversely correlated to the de-
gree of virus attenuation, such that the most effective
designs retain considerable pathogenic potential.12 Even if
the vaccine strain can be tuned to be safe, one cannot
preclude that pathogenic variants arise via spontaneous
virus evolution.13 Insertional oncogenesis and leukemia in-
duction also remains a possibility. Despite the incorporation
of safety features, such as drug-controlled gene switches,14
these concerns have precluded the further development of
live, attenuated HIV strains as human vaccines.
HIV-induced leukemia
Untreated HIV infection causes acquired immune deficiency
syndrome (AIDS) and this major impairment in the immune
system is e not surprisingly e associated with an increased
risk of cancer, including a number of “solid tumor” cancers
and non-Hodgkin lymphoma, but also Hodgkin lymphoma,
myeloma and leukemia. Research continues on how to fine
tune the therapeutic regimens in these patients, which
range from different combinations of chemotherapy and
antiretroviral therapy to stem cell transplants. Perhaps
surprisingly, there is little evidence that active HIV repli-
cation and the numerous integration events into the host
cell genome that occur during the lifetime of an HIV-
infected individual is directly linked to these HIV-associated
cancers via insertional oncogenesis. A likely explanation is
that the infected cells have a very short half life because
they are recognized and removed by the immune system.
A functional HIV cure due to leukemia
treatment
Several new antiviral strategies have been proposed and
were recently reviewed.15,16 Then there is that remarkable
therapeutic success that connects HIV and leukemia.17 Forthe first time in medical history, an HIV patient seems to
have been cured from the disease. The patient underwent a
stem cell transplant in the hopes of treating his leukemia,
but ended up being cured of both the leukemia and HIV.
The stem cells used for the transplant came from a donor
who carried the d-32 deletion in the CCR5 gene that dis-
rupts the expression of this major receptor for HIV entry
into cells. Once the patient received the transplant, he
stopped taking the antiretroviral drugs that had been
managing his virus infection. The virus did not reappear in
his blood, although one may suspect that it is still lurking
somewhere in his body.17
Now some 5 years later, the doctor has declared him HIV-
free, as the patient’s CD4 cell count falls within the range
of an uninfected person.18 Functional cure is perhaps the
best description and one should realize that such a trans-
plant is too risky and taxing to offer to HIV-infected in-
dividuals. Nevertheless, this clinical result has spurred
many alternative gene therapeutic approaches to inacti-
vate the CCR5 gene,19 to silence CCR5 gene expression20 or
to inhibit HIV by other means.21 An attractive vehicle to
deliver the antiviral payload is again the lentiviral vector
system.22,23
Summary
Several preclinical studies and clinical successes were
presented, demonstrating that there is much progress in
the field of molecular medicine. This has been facilitated
by the delineation of molecular pathways and the detailed
dissection of disease processes. Progress is particularly
obvious for the field of gene therapy, which showsdafter a
difficult initial phasedthat therapeutic efficacy and safety
can go hand in hand. HIV research led to the discovery of
many new molecular mechanisms and this insight has
spurred several original therapeutic strategies. HIV is not
only the target for therapeutic intervention, this virus has
also provided one of the favorite tools for efficient gene
therapy in the form of lentiviral vector systems. Using this
molecular knowledge base, novel tailor-made therapeutic
strategies can be designed that will eventually change the
way we treat patients. The recent progress in molecular
medicine has been spectacular, and it seems only a matter
of time before some approaches will translate to im-
provements in patient care.
Acknowledgments
This work was supported in part by grants from ZonMw
(Translational gene therapy program), NWO-CW (Top grant)
and the Aids Fonds Netherlands.
References
1. Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A,
Morillon E, et al. Insertional oncogenesis in 4 patients after
retrovirus-mediated gene therapy of SCID-X1. J Clin Invest
2008;118:3132e42.
2. Hacein-Bey-Abina S, Hauer J, Lim A, Picard C, Wang GP,
Berry CC, et al. Efficacy of gene therapy for X-linked severe
combined immunodeficiency. N Engl J Med 2010;363:355e64.
444 B. Berkhout3. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G,
Schmidt M, Kutschera I, et al. Hematopoietic stem cell gene
therapy with a lentiviral vector in X-linked adrenoleukodys-
trophy. Science 2009;326:818e23.
4. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric an-
tigen receptor-modified T cells in chronic lymphoid leukemia.
N Engl J Med 2011;365:725e33.
5. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al.
T cells with chimeric antigen receptors have potent antitumor
effects and can establish memory in patients with advanced
leukemia. Sci Transl Med 2011;3:95ra73.
6. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED.
Antileukemic effect of chronic graft-versus-host disease:
contribution to improved survival after allogeneic marrow
transplantation. N Engl J Med 1981;304:1529e33.
7. Molina A. A decade of rituximab: improving survival outcomes
in non-Hodgkin’s lymphoma. Annu Rev Med 2008;59:237e50.
8. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF,
Romel L, et al. A controlled trial of intratumoral ONYX-015, a
selectively-replicating adenovirus, in combination with
cisplatin and 5-fluorouracil in patients with recurrent head and
neck cancer. Nat Med 2000;6:879e85.
9. Jeeninga RE, Jan B, van der Linden B, van den Berg H,
Berkhout B. Construction of a minimal HIV-1 variant that
selectively replicates in leukemic derived T-cell lines: towards
a new virotherapy approach. Cancer Res 2005;65:3347e55.
10. Jeeninga RE, Jan B, van den Berg H, Berkhout B. Construction of
doxycyline-dependent mini-HIV-1 variants for the development
of a virotherapy against leukemias. Retrovirology 2006;3:64.
11. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC.
Protective effects of a live attenuated SIV vaccine with a
deletion in the nef gene. Science 1992;258:1938e41.
12. Baba TW, Liska V, Khimani AH, Ray NB, Dailey PJ, Penninck D,
et al. Live attenuated, multiply deleted simian immunodefi-
ciency virus causes AIDS in infant and adult macaques. Nat Med
1999;5:194e203.13. Berkhout B, Verhoef K, van Wamel JL, Back NK. Genetic
instability of live, attenuated human immunodeficiency virus
type 1 vaccine strains. J Virol 1999;73:1138e45.
14. Das AT, Klaver B, Centlivre M, Harwig A, Ooms M, Page M, et al.
Optimization of the doxycycline-dependent simian immuno-
deficiency virus through in vitro evolution. Retrovirology 2008;
5:44.
15. Lever RA, Lever AM. Intracellular defenses against HIV, viral
evasion and novel therapeutic approaches. J Formos Med Assoc
2011;110:350e62.
16. Vanham G, Van GE. Can immunotherapy be useful as a "func-
tional cure" for infection with human immunodeficiency virus-
1? Retrovirology 2012;9:72.
17. Hutter G, Nowak D, Mossner M, Ganepola S, Mussig A, Allers K,
et al. Long-term control of HIV by CCR5 d32/d32 stem-cell
transplantation. N Engl J Med 2009;360:692e8.
18. Allers K, Hutter G, Hofmann J, Loddenkemper C, Rieger K,
Thiel E, et al. Evidence for the cure of HIV infection by CCR5-
d32/d32 stem cell transplantation. Blood 2010;117:2791e9.
19. Cannon P, June C. Chemokine receptor 5 knockout strategies.
Curr Opin HIV AIDS 2011;6:74e9.
20. DiGiusto DL, Krishnan A, Li L, Li H, Li S, Rao A, et al. RNA-based
gene therapy for HIV with lentiviral vector-modified CD34(þ)
cells in patients undergoing transplantation for AIDS-related
lymphoma. Sci Transl Med 2010;2:36ra43.
21. Ter Brake O, Legrand N, von Eije KJ, Centlivre M, Spits H,
Weijer K, et al. Evaluation of safety and efficacy of RNAi
against HIV-1 in the human immune system (Rag-2(/)
gc(/)) mouse model. Gene Ther 2009;16:148e53.
22. Liu YP, Westerink JT. Ter Brake O, Berkhout B. RNAi-inducing
lentiviral vectors for anti-HIV-1 gene therapy. Methods Mol
Biol 2011;721:293e311.
23. Walker JE,ChenRX,McGeeJ,NaceyC,PollardRB,AbediM,et al.
Generation of an HIV-1-resistant immune system with CD34(þ)
hematopoietic stem cells transduced with a triple-combination
anti-HIV lentiviral vector. J Virol 2012;86:5719e29.
